Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study-Reference-Cited by-同舟云学术

Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study

Published:2023-04-21 Issue:10 Volume:60 Page:1862-1868
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Cakmak Mehmet Erdem¹^ORCID,Öztop Nida¹^ORCID,Yeğit Osman Ozan¹^ORCID,Özdedeoğlu Özlem¹^ORCID

Affiliation:

1. Department of Allergy and Clinical Immunology, Istanbul Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Pediatrics, Perinatology and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/02770903.2023.2196562

Reference24 articles.

1. Global Initiative for Asthma (GINA). Available from: http://www.ginasthma.org. [last accessed 10 Jan 2023].

2. Severe asthma phenotypes in patients controlled with omalizumab: A real-world study

3. Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history

4. Omalizumab: Anti-IgE Therapy in Allergy

5. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study;International Archives of Allergy and Immunology;2023-11-22